slashing

MicroStockHub U.K.-listed shares of Indivior (NASDAQ:INDV) lost more than a third on Tuesday after the pharma company lowered its FY 2024 financial outlook, citing, among other things, sales headwinds related to Sublocade, a prescription drug indicated for opioid use disorder. Indivior (INDV), based in North Chesterfield, Virginia, also announced aContinue Reading